WASHINGTON, March 29 (Reuters) - Medtronic Inc's minimally invasive CoreValve system for replacing diseased aortic heart valves led to a significantly higher survival rate after one year than ...
Nontransfemoral implantation, however, was not an independent predictor of mortality and likely reflected the higher risk of the patients treated this way. What's to Be Gleaned From UK TAVI? Speaking ...
The race for a new type of heart valve is getting serious. Last week, Medtronic Inc. said it is paying $700 million plus future payments to buy CoreValve Inc., an Irvine up-and-comer in heart valves ...
Patients implanted with the CoreValve transcatheter aortic valve replacement showed strong blood flow and improved quality of life at five years post-implant, according to results from two Medtronic ...
Patients receiving Medtronic's CoreValve system, a device for transcatheter aortic valve implantation, experienced immediate and long-term health-related quality-of-life benefits, according to ...
ANN ARBOR, Mich. – The University of Michigan Cardiovascular Center, a leader in heart valve replacement, will participate in a national clinical trial to offer patients a less invasive approach to ...
CHICAGO, IL — The largest-ever review of transcatheter aortic-valve replacement (TAVR) procedures for failed bioprosthetic valves suggests that TAVR could play a key role in solving a problem that ...
Edwards Lifesciences Inc. says it will appeal a Delaware judge’s decision not to bar the manufacture and sale of Medtronic Inc.’s CoreValve aortic valve replacement. Medtronic Inc. (NYSE:MDT) managed ...
Wall Street and others are continuing to weigh in on Medtronic Inc.’s pending $700 million buy of Irvine device maker CoreValve Inc. Medtronic, which employs some 550 people at its Santa Ana heart ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results